New Delhi: American pharma company Johnson & Johnson has submitted an application to the Central Drugs Standard Control Organization (CDSCO), seeking permission to study a COVID-19 single shot vaccine in India in adolescents aged 12 to 17 years.
Earlier this month, Union Health Minister Mansukh Mandaviya informed that Johnson & Johnson’s single-dose Kovid-19 vaccine had been approved for emergency use in India.
Mansukh Mandaviya said, “India expands its vaccine basket! Johnson & Johnson’s single-dose COVID-19 vaccine has been approved for emergency use in India. Now India has 5 EUA vaccines. The collective fight of will get further impetus.”
The vaccine maker has claimed that its single-shot COVID-19 vaccine has shown promising signs of protection against the rapidly spreading delta variant in the US and other countries.
Earlier this year the Drug Controller General of India in May allowed Bharat Biotech to conduct clinical trials for its vaccine, Covaxin, on healthy volunteers aged 2 to 18 years. Apart from Bharat Biotech, Zydus Cadila, which is developing DNA vaccines, is also conducting its own clinical trials for the age group of 12 to 18 years.
India Vaccine Coverage
Meanwhile, India’s COVID-19 vaccination coverage has achieved a significant milestone of over 50 crore (57,16,71,264) with over 48 lakh (48,84,440) vaccine doses administered in the last 24 hours.
26,66,831 doses of vaccine were administered as first dose and 6,01,437 doses of vaccine were administered as second dose in the age group of 18-44 years today. Overall, 21,13,11,218 persons in the age group of 18-44 years across 37 States/UTs have received their first dose and a total of 1,79,43,325 people have received their first dose since the start of the third phase of the vaccination campaign. Received your second dose.
See below health equipment-
Calculate your body mass index (BMI)
.